JACC: CardioOncology Pulse - SGLT2 Inhibitors and Withdrawal of Neurohormonal Therapy in Cancer Therapy-Related Cardiotoxicity: What Is the Evidence?
Release Date:
JACC: CardioOncology Editor-in-chief, Bonnie Ky, MD, MSCE, FACC and Dinesh Thavendiranathan, MD, MSc, Husam Abdel-Qadir, MD, PhD and Christopher Yu, MBBS discuss recent studies of SGLT2 inhibitors and withdrawal of neurhormonal therapy for cancer therapy-related cardiotoxicity.
JACC: CardioOncology Pulse - SGLT2 Inhibitors and Withdrawal of Neurohormonal Therapy in Cancer Therapy-Related Cardiotoxicity: What Is the Evidence?